.jpg "/Content/Upload/Product/Human_ELISA_kits_Diagnocine_1200_1200(92).jpg")
Human Vascular Endothelial cell Growth Factor D,VEGF-D ELISA KIT
The Ultimate 1-Stop ELISA Marketplace:
60,000+ ELISA kits Available to Serve Scientists from All Fields of Life Science
Always Powered by Diagnocine for Precision Research.
Most comprehensive buffers, reagents and detection agents are provided with each kit to optimize data output.
All-inclusive format covers everything from sample preparation to signal detection. Every step can be customized and optimized for your precision research.
DiagnoCine Precision buffers and reagents are Made in USA ISO 13485 Certified
Why waste time searching for your ELISA kit when you can get everything in one place? Diagnocine can provide you with all the ELISA needs you have (customized ELISAs also available) on the planet through a single, streamlined ordering process.
* all types of species
* HRP and AP detection
* Low target signal enhancement
* Inquire about a trial version or a customized version
4 core reagents below are included with every order, plus 1 of the 2 detection-specific reagents (matched automatically to your kit type) — 5 components, every time.
+ the 5th component, matched to your kit's detection method:
If you have any questions or need additional information, please call us at 551-245-1033 or email us at support@diagnocine.com. Our team will be happy to assist you.
Universal Compatibility
All buffers and detection reagents work seamlessly across target proteins, bridging the gap in assay consistency.
1-Stop Convenience
Consolidate your lab's purchasing. Source all ELISA needs and experience optimal buffers and reagents in a single shipment.
Enhanced Precision
Designed by scientists for scientists, all components are engineered to deliver sharper results and an optical signal.
Human Vascular Endothelial cell Growth Factor D,VEGF-D ELISA KIT
Quantitative immunoassay for c-fos induced growth factor (vascular endothelial growth factor D) in human serum, plasma, tissue homogenates available in multiple catalog sizes:
Note: Please send inquiries regarding Trial 24T orders to support@diagnocine.com.
| Target name | c-fos induced growth factor (vascular endothelial growth factor D) |
| Uniprot No. | O43915 |
| Species | Homo sapiens (Human) |
| Sample types | serum, plasma, tissue homogenates |
| Detection range | 31.25 pg/ml - 2000 pg/ml |
| Sensitivity | 7.81 pg/ml |
| Assay time | 1-5h |
| Sample loading volume | 50-100μL |
| Detection wavelength | 450 nm |
| Assay principle | Quantitative |
| Data analysis | Standard curve + Curve Expert software |
| Research area | Cardiovascular |
| Storage condition | 2-8°C (see protocol for full details) |
| Shipping condition | 4 °C |
| Shelf life | 6 months |
10 business days
Processing + 3-5 days shipping
In Stock : USA
Worldwide shipping available
Immunoreaction
450 nm detection
Standard curve
Quantification
Quantification uses a standard curve fitted with Curve Expert software, covering 31.25 pg/ml - 2000 pg/ml with a minimum detectable dose of 7.81 pg/ml.
The human VEGFD ELISA Kit is intended to measure human VEGFD in serum, plasma, or tissue homogenates. This assay uses the bi-antibody sandwich technique and enzyme-substrate chromogenic reaction to quantify human VEGFD concentration. The intensity of the colored product is directly proportional to the concentration of VEGFD present in the sample. This human VEGFD ELISA kit has high specificity and excellent sensitivity.
VEGFD is a secreted glycoprotein that can activate VEGFR-2 and VEGFR-3 on the endothelium and acts as a mitogen for endothelial cells to promote the growth and remodeling of blood vessels and lymphatic vessels. VEGFD is a potential biomarker for lymphangioleiomyomatosis. It has been demonstrated that high serum levels of VEGFD are linked to atrial fibrillation, ischemic stroke, and heart failure. Elevated VEGFD values have recently been associated with all-cause mortality in individuals with coronary artery disease.
- The most extensively accepted signaling pathways promoting lymphangiogenesis in tumors include the secreted lymphangiogenic proteins: VEGF-C and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3). PMID: 26706909
- Study demonstrated that VEGF-D upregulates myofibroblast proliferation, migration, and collagen synthesis through activation of VEGF pathway. PMID: 26724950
- CCL21/CCR7 induce VEGF-D up-regulation and promote lymphangiogenesis via ERK/Akt pathway in lung cancer. PMID: 26884842
- VEGF-D and its receptors were co-localized on blood vessels in clinical samples of human lungs exposed to hyperoxia; hence, VEGF-D may act directly on blood vessels to promote fluid leak. PMID: 26924464
- Taken together, our data suggest that TNF-alpha can promote lymphangiogenesis and lymphatic metastasis of GBC through the ERK1/2/AP-1/VEGF-D pathway. PMID: 26992854
- VEGF-D-enhanced metastasis was evidently reversed by MP. MP significantly reduced the invasion of VEGFD-SK cells, tumor volume, lymphatic metastasis rates and lymphatic vessel density compared with control groups PMID: 27211072
- Sulf2 facilitated lymphangiogenesis in breast cancer cells by regulating VEGF-D and that the AKT1related signaling pathway was involved. PMID: 27748846
- High VEGFD expression is associated with angiogenesis and lymphangiogenesis. PMID: 27852824
- VEGF-D-induced changes in serine/threonine kinase mTOR shuttling between the cytosol and nucleus and its increased phosphorylation at Ser-2448, lead us to the conclusion that the observed shift in redox balance is regulated via mTOR kinase signalling. PMID: 27957793
- High VEGFD expression is associated with lymphangioleiomyomatosis. PMID: 28202529
- no difference in the levels of VEGF-A, VEGF-C, and VEGF-D in pre-eclampsia compared to normotensive pregnant women stratified by HIV status PMID: 28524736
- CXCR4, CCR7, VEGF-C and VEGF-D expression might have synergistic effects on the lymph node metastasis in patients with cervical cancer. PMID: 28535405
- Data show that VEGF-C, VEGF-D, and VEGFR-3 were expressed in a substantial percentage of breast carcinomas. PMID: 28791841
- SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D. PMID: 29075785
- Serum VEGF-D levels were significantly increased in definite lymphangioleiomyomatosis (LAM) patients compared with healthy controls. Serum VEGF-D levels were significantly increased in definite LAM patients who had chylothorax compared with those without chylothorax. PMID: 29906075
Intra-assay Precision (Precision within an assay): CV%<8% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three samples of known concentration were tested twenty times on one plate to assess. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inter-assay Precision (Precision between assays): CV%<10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three samples of known concentration were tested in twenty assays to assess. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. | |||||||||||||
| |||||||||||||
pg/ml | OD1 | OD2 | Average | Corrected | |||||||||
2000 | 2.436 | 2.568 | 2.502 | 2.352 | |||||||||
1000 | 2.062 | 2.132 | 2.097 | 1.947 | |||||||||
500 | 1.457 | 1.444 | 1.451 | 1.301 | |||||||||
250 | 0.760 | 0.789 | 0.775 | 0.625 | |||||||||
125 | 0.486 | 0.458 | 0.472 | 0.322 | |||||||||
62.5 | 0.372 | 0.360 | 0.366 | 0.216 | |||||||||
31.25 | 0.255 | 0.247 | 0.251 | 0.101 | |||||||||
0 | 0.152 | 0.148 | 0.150 |
| |||||||||
To assess the linearity of the assay, samples were spiked with high concentrations of human VEGF-D in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | ||||||||||||
| Sample | Serum(n=4) | ||||||||||
1:1 | Average % | 95 | ||||||||||
Range % | 88-98 | |||||||||||
1:2 | Average % | 102 | ||||||||||
Range % | 92-106 | |||||||||||
1:4 | Average % | 98 | ||||||||||
Range % | 89-102 | |||||||||||
1:8 | Average % | 94 | ||||||||||
Range % | 87-98 | |||||||||||
The recovery of human VEGF-D spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | ||||||||||||
Sample Type | Average % Recovery | Range% | ||||||||||
Serum (n=5) | 91 | 84-96 | ||||||||||
EDTA plasma (n=4) | 99 | 91-103 | ||||||||||
